US-based drug discovery and development service company Crown Bioscience and Horizon Discovery have entered into a two year collaboration agreement to provide combined solutions for in vivo model development.
Under the partnership, Horizon will share its X-Gene Mutant and Normal (X-MAN ) cell lines with Crown who will provide animal model development, study execution and business marketing to its clients.
Horizon Discovery CEO Darrin Disley said the suite of in vivo models developed with Crown will complement the company's extensive range of in vitro drug discovery tools and services.
"This collaboration is further testament to the power and utility of Horizon's gene editing technology in the creation of high value drug discovery tools," Disley added.
Crown Bioscience president Jean-Pierre Wery said, "We are excited to continue working with Horizon through this new collaboration, and believe that the project will bring us closer to achieving a global leadership position in supporting oncology drug discovery programs."
